Comparison of Clomiphene Citrate Alone with Combination of Clomiphene Citrate Plus Gonadotropin in Achieving Pregnancy with Unexplained Infertility
DOI:
https://doi.org/10.59119/ajms.2021(1).1.3Keywords:
Unexplained Infertility, Occurrence of pregnancy, Gonadotropins, Clomiphene Citrate.Abstract
Background: Infertility is the most common problem faced by couples now days. According to statistics 2023 approximately 48.5 million couples faced infertility worldwide.
Objective: Our study's objective was to examine the effectiveness of clomiphene citrate alone vs a combination of clomiphene citrate and gonadotropin in helping patients with unexplained infertility become pregnant.
Methods: : : A total of seventy-two patients, 20 to 35 years of age with unexplained infertility were included, through a randomized control trial in MCH center of PIMS, Islamabad. Patients with history of taking medicines such dopamine dilators, dopamine receptor blockers, H-2 blockers, and verapamil as well as other reasons of infertility included tubal factors, male factors, and hyperprolactinemia were excluded. All patients were divided into two groups i.e. Group A (clomiphene citrate) & Group B (clomiphene citrate plus gonadotropin). Outcome variables like efficacy i.e. occurrence of pregnancy, were noted.
Results: In groups A and B the mean age was 26.73 3.49 and 27.20 3.35, respectively. The average marriage lasted 4.17 ± 2.12 years in group A and 4.39 2.27 years in group B. Group A (the clomiphene citrate group) efficacy was 15 (41%) while Group B (the combination of clomiphene citrate and gonadotropin) efficacy was 28 (77%) with a p-value of 0.005.
Conclusion: The conclusion of the study was that efficacy of clomiphene citrate plus gonadotropin combination in achieving pregnancy in patients with unexplained infertility is higher compared to clomiphene citrate only.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Avicenna Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.